Prefunding prescription drugs for seniors necessary

Feb 09, 2010 By Ken McGuffin

(PhysOrg.com) -- A prefunded plan where Canadians would contribute to a dedicated fund during their working years to pay for their prescription drugs when they reach 65 would help protect public health care, according to the new IRPP Study, "Providing Pharmacare for an Aging Population: Is Prefunding the Solution?"

The growth rate of spending on has exceeded the growth rate of overall expenditures. In addition, the elderly are more likely to need pharmaceuticals both now and in the future, and this need for pharmaceuticals is more evenly distributed across the elderly population than is the need for health care services more generally.

"This rapid growth, coupled with the pattern of prescription among seniors, make this type of expense a strong candidate for prefunding," says co-author Mark Stabile, an associate professor of business economics at the Rotman School of Management. He is also director of the university's School of Public Policy and Governance.

"If they are not addressed, these future expenditures could potentially lead to further crowding out of other social services within provincial budgets."

The authors propose making this program mandatory. This would ensure that individuals are able to afford their drug expenses when they reach old age, and it addresses the problem of healthy people opting out of the program, which would ultimately undermine both cost- and risk-sharing.

This video is not supported by your browser at this time.

The authors acknowledge that prefunding is not without its challenges, which include transition issues and the difficult design choices that would be required to preserve efficiency and fairness. The limits of prefunding medicare are discussed in the commentary by Michel Grignon, who presents opposing arguments to prefunding as the solution to the increasing health costs associated with an .

Explore further: FDA approves new drug for rare genetic disease

More information:
Study: www.irpp.org/pubs/IRPPstudy/IRPP_Study_no2.pdf
Summary: www.irpp.org/newsroom/archive/2010/0209sume.pdf

add to favorites email to friend print save as pdf

Related Stories

Seniors in Medicare's doughnut hole decrease use of meds

Feb 03, 2009

Beneficiaries enrolled in Medicare Part D who reached a gap in health care coverage known as the "doughnut hole" were much less likely to use prescription drugs than those with an employer-based plan, according to a University ...

Study addresses impact of Medicare Part D on medical spending

Jul 01, 2009

After enrolling in Medicare Part D, seniors who previously had limited or no drug coverage spent more on prescriptions and less on other medical care services such as hospitalizations and visits to the doctor's office, according ...

Drug benefit expanded to 1 million more seniors

Jan 08, 2010

(AP) -- In case the prospect of nearly $4,000 in prescription assistance isn't enough to perk up low-income seniors, the government is using '60s singer Chubby Checker to publicize "the twist" in the Medicare ...

Clinical pharmacists can reduce drug costs

Dec 23, 2008

Clinical pharmacy services can significantly reduce the cost of prescription drugs and save money elsewhere in the health care system, according to a new study by researchers at the University of Illinois at Chicago.

Medicare drug plan changes affect seniors

Oct 04, 2006

U.S. officials say changes in the Medicare prescription drug plan for next year will include more choices and better coverage especially in the "doughnut hole."

Recommended for you

Boxed warnings are common in novel therapeutics

20 hours ago

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

21 hours ago

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

22 hours ago

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments : 0